Advanced or Metastatic Solid Tumors Clinical Trials

84 clinical trials for Advanced or Metastatic Solid Tumors across international registries, including 16 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• A Study to Learn About the Study Medicine Called PF-07799544 as Monotherapy or in Combination in People With Advanced Solid Tumors — RECRUITING · PHASE1
• Dose Escalation and Expansion Study of BH3120 Alone or With Pembrolizuamb in Advanced or Metastatic Solid Tumors — RECRUITING · PHASE1
• A Study of SHY-ONC6, a Novel Proteasome Inhibitor, in Adults With Advanced or Metastatic Solid Tumors — RECRUITING · PHASE1
• To Evaluate the Safety, Tolerability, Pharmacokinetics and Antitumor Activity of DAY301 in Participants With Locally Advanced or Metastatic Solid Tumors — RECRUITING · PHASE1
• A Study of TAK-188 in Adults With Advanced or Spreading Solid Tumors — RECRUITING · PHASE1
• A Clinical Study of KK2260 in Patients With Advanced or Metastatic Solid Tumors — RECRUITING · PHASE1
• A Phase I Study to Investigate the Safety and Tolerability of KGX101 Monotherapy and Combination Therapy With Envafolimab in Advanced or Metastatic Solid Tumor Patients — RECRUITING · PHASE1
• PRISM-NK: Precision-Matched Allogeneic Single- or Dual-Target CAR-NK Cells for Advanced Solid Tumors — RECRUITING · PHASE1
• A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies — RECRUITING · PHASE1
• A First-in-human Study of PRTH-101 Monotherapy +/- Pembrolizumab in Subjects With Advanced Malignancies — RECRUITING · PHASE1
• Study to Assess the Safety, Tolerability, and Blood Concentration of PMC-309 — RECRUITING · PHASE1
• Dose Escalation and Expansion Study of HM16390 Alone or With Pembrolizumab in Advanced or Metastatic Solid Tumors — RECRUITING · PHASE1
• A Phase 1 Study of LNCB74 in Advanced Solid Tumors — RECRUITING · PHASE1
• DCSZ11 as a Monotherapy and in Combination in Patients With Advanced or Metastatic Solid Tumors — RECRUITING · PHASE1
• Pan-T Booster Co-expressing MSLN CAR T Cell Therapy in Advanced/Metastatic Solid Tumors — RECRUITING · PHASE1
• A Phase 1 Study to Evaluate TGI-6 in Subjects With Locally Advanced/Metastatic Solid Tumors — RECRUITING · PHASE1
• A Safety, Tolerability and Efficacy Study of NC410 Plus Pembrolizumab in Participants With Advanced Unresectable or Metastatic Solid Tumors — TERMINATED · PHASE1
• Dose Escalation and Expansion Study of HM97662 in Advanced or Metastatic Solid Tumors — ACTIVE_NOT_RECRUITING · PHASE1
• A Phase I/II, Open-Label, Multicenter Study of ALE.P03 (Claudin-1 Targeted Antibody-Drug Conjugate) as a Monotherapy in Adult Patients with Selected Advanced or Metastatic CLDN1+ Solid Tumors — TERMINATED · PHASE2
• A Study of MK-1484 as Monotherapy and in Combination With Pembrolizumab (MK-3475) In Advanced or Metastatic Solid Tumors (MK-1484-001) — ACTIVE_NOT_RECRUITING · PHASE1
• Safety and Tolerability of IPH4502 in Patients With Advanced Solid Tumors — ACTIVE_NOT_RECRUITING · PHASE1
• Phase I Study of Single-Agent KGX105 in Patients With Advanced or Metastatic Solid Tumors — NOT_YET_RECRUITING · PHASE1
• Phase 1 Study of OP-3136 in Advanced or Metastatic Solid Tumors — TERMINATED · PHASE1
• A Study of MK-6598 as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Advanced Solid Tumors (MK-6598-001) — COMPLETED · PHASE1
• A Study of PARG Inhibitor IDE161 in Participants With Advanced Solid Tumors — ACTIVE_NOT_RECRUITING · PHASE1
• A Phase 1, Open-Label, Multicenter Study of INCB161734 in Participants With Advanced or Metastatic Solid Tumors with KRAS G12D Mutation — COMPLETED · PHASE1
• A Study of ERAS-007 as Monotherapy or in Combination With ERAS-601 in Patients With Advanced or Metastatic Solid Tumors — ACTIVE_NOT_RECRUITING · PHASE1
• A Phase 1, Open-Label, Multicenter Study of INCB123667 as Monotherapy and in Combination With Anticancer Therapies in Participants With Selected Advanced Solid Tumors — TERMINATED · PHASE1
• A Study to Evaluate the Bioavailability of Pembrolizumab (MK-3475) Via Subcutaneous (SC) Injection of Pembrolizumab Formulated With Berahyaluronidase Alfa (MK-5180) [MK-3475A] In Advanced Solid Tumors (MK-3475A-C18) — COMPLETED · PHASE1
• A Study of MRG004A in Patients With Tissue Factor Positive Advanced or Metastatic Solid Tumors — COMPLETED · PHASE1
• This is an Open Label, Two-part, Multicenter, Phase I Trial to Investigate the Safety, Tolerability, and PK of KGX101 Monotherapy and Combination Therapy With Envafolimab in Patients With Advanced or Metastatic Solid Tumors. — ACTIVE_NOT_RECRUITING · PHASE1
• Assessment of Safety, Tolerability and Pharmacokinetics With BAT8010 for Injection in Advanced Malignant Solid Tumors Patients — COMPLETED · PHASE1
• A Dose Escalation/Expansion Study of ERAS-601 in Patients With Advanced or Metastatic Solid Tumors — ACTIVE_NOT_RECRUITING · PHASE1
• A Study to Assess Naporafenib (ERAS-254) Administered With Trametinib in Patients With RAS Q61X Mutations — ACTIVE_NOT_RECRUITING · PHASE1
• An Open-Label, Multicenter, First-in-Human, Phase 1 Dose Escalation and Multicohort Expansion Study of INBRX-109 in Subjects with Locally Advanced or Metastatic Solid Tumors, Including Sarcomas. — TERMINATED · PHASE2
• A Phase 1b/2 Multisite Dose-finding and Expansion Study of WTX-330 in Adult Patients With Selected Advanced or Metastatic Solid Tumors or Lymphoma — ACTIVE_NOT_RECRUITING · PHASE1
• A Phase 1, Open-Label, Multicenter Study of INCA033890 in Participants with Advanced or Metastatic Solid Tumors — TERMINATED · PHASE1
• A Study of Orally Administered MOMA-313 in Participants with Advanced or Metastatic Solid Tumours — TERMINATED · PHASE1
• WTX-330 in Patients With Advanced or Metastatic Solid Tumors or Non-Hodgkin Lymphoma — COMPLETED · PHASE1
• A Study of TAK-981 Given With Pembrolizumab in Participants With Select Advanced or Metastatic Solid Tumors — COMPLETED · PHASE1
• A Phase 1a/1b Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of BGB-A3055, Alone and in Combination With Tislelizumab in Patients With Selected Advanced or Metastatic Solid Tumors — OTHER · PHASE1
• A Phase I/II Open-label Dose Escalation and Dose Expansion Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of AZD5863, a T cell-engaging Bispecific Antibody that Targets Claudin 18.2 (CLDN18.2) and CD3 in Adult Participants with Advanced or Metastatic Solid Tumors. — TERMINATED · PHASE2
• This study aims to find the best dose of BI 907828 (brigimadlin) in patients with different types of advanced cancer (solid tumors) — OTHER · PHASE1
• A Phase I Study of ONO-4538HSC in Subjects With Advanced or Metastatic Solid Tumors — ACTIVE_NOT_RECRUITING · PHASE1
• A Phase II, Open-label, Multi-center, Basket Study of the ATR Kinase Inhibitor ART0380 Administered Orally as Monotherapy to Patients with Biologically Selected Advanced or Metastatic Solid Tumors (ARTIST) — OTHER · PHASE2
• Study of ONO-4578 With and Without ONO-4538 in Subjects Advanced or Metastatic Solid Tumors — ACTIVE_NOT_RECRUITING · PHASE1
• A Safety and Tolerability Study of NC762 in Subjects With Advanced or Metastatic Solid Tumors — TERMINATED · PHASE1
• A Phase 1/2 Study of VIO-01 in Participants With Recurrent Solid Tumors — TERMINATED · PHASE1
• A Study of TAS0612 in Participants With Advanced or Metastatic Solid Tumor Cancer — TERMINATED · PHASE1
• A Study of AK119 (Anti-CD73) in Combination With AK104 in Subjects With Advanced Solid Tumors — COMPLETED · PHASE1

Refine this search